Haplotype of platelet receptor P2RY12 gene is associated with residual clopidogrel on-treatment platelet reactivityP2RY12 基因单倍体分型对急性冠脉综合征患者氯吡格雷用药后血小板反应性的影响

[1] Angiolillo D.J.(2005)Lack of association between the P2Y Thromb. Res. 116 491-497

[2] Fernandez-Ortiz A.(2007) receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease J. Am. Coll. Cardiol. 49 1505-1516

[3] Bernardo E.(2005)Variability in individual responsiveness to clopidogrel:clinical implications, management, and future perspectives J. Am. Coll. Cardiol. 46 761-769

[4] Angiolillo D.J.(2008)Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial Br. J. Clin. Pharmacol. 65 540-547

[5] Fernandez-Ortiz A.(2007) polymorphisms and antiplatelet effects of aspirin in patients with coronary artery disease J. Am. Coll. Cardiol. 49 657-666

[6] Bernardo E.(2008)Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate J. Am. Coll. Cardiol. 52 531-533

[7] Beinart S.C.(2010)The association of cigarette smoking with enhanced platelet inhibition by clopidogrel Thromb. Res. 125 e167-e170

[8] Kolm P.(2007)Impact of P2Y12-ADP receptor polymorphism on the efficacy of clopidogrel dose-adjustment according to platelet reactivity monitoring in coronary artery disease patients BMC Med. Genet. 8 59-697

[9] Veledar E.(2014)Gene sequence variations of the platelet P2Y J. Am. Coll. Cardiol. 64 C203-899

[10] Bierend A.(2010) receptor are associated with coronary artery disease J. Immunol. 185 688-404

[1] Angiolillo D.J.(2005)Lack of association between the P2Y Thromb. Res. 116 491-497

[2] Fernandez-Ortiz A.(2007) receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease J. Am. Coll. Cardiol. 49 1505-1516

[3] Bernardo E.(2005)Variability in individual responsiveness to clopidogrel:clinical implications, management, and future perspectives J. Am. Coll. Cardiol. 46 761-769

[4] Angiolillo D.J.(2008)Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial Br. J. Clin. Pharmacol. 65 540-547

[5] Fernandez-Ortiz A.(2007) polymorphisms and antiplatelet effects of aspirin in patients with coronary artery disease J. Am. Coll. Cardiol. 49 657-666

[6] Bernardo E.(2008)Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate J. Am. Coll. Cardiol. 52 531-533

[7] Beinart S.C.(2010)The association of cigarette smoking with enhanced platelet inhibition by clopidogrel Thromb. Res. 125 e167-e170

[8] Kolm P.(2007)Impact of P2Y12-ADP receptor polymorphism on the efficacy of clopidogrel dose-adjustment according to platelet reactivity monitoring in coronary artery disease patients BMC Med. Genet. 8 59-697

[9] Veledar E.(2014)Gene sequence variations of the platelet P2Y J. Am. Coll. Cardiol. 64 C203-899

[10] Bierend A.(2010) receptor are associated with coronary artery disease J. Immunol. 185 688-404